Indication: Cystic Fibrosis
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
Sub-indication: Cystic Fibrosis
Study Type: Drug Study
Principal Investigator: Adrian O'Hagan, M.D.Norton Children's Pulmonology, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Vertex Pharmaceuticals, Inc.
Email for more information: NCRI-Pulm@NortonHealthcare.org